This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Filed in Maryland district court, the lawsuit claims the biotech unjustly profited from using HeLa cells to develop AAV vectors for its gene therapy products.
As one of the more recent fields to emerge in the clinical space, psychedelics have gained significant traction as a potential treatment for various neuropsychiatric diseases. With so many exciting developments in the last few years, it’s critical for the psychedelic community to come together to reflect on our progress, share the latest discoveries, and discuss the future of psychedelic research.
The global COVID-19 pandemic has shown us just how devastating these outbreaks can be – and it could have been much worse. Now, scientists have developed an AI application that promises to warn us about dangerous variants in future pandemics.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
The acquisition follows a similar-sized, obesity-focused buyout by Eli Lilly last month and hands Novo a weight-loss medicine already in mid-stage testing.
Responding (or Not) to Signals of Potential Clinical Significance in Pragmatic Clinical Trials Description Joseph Ali, Tanya Matthews, and Leslie J. Crofford discuss responding (or not) to signals of potential clinical significance in pragmatic clinical trials. Biography Joseph Ali, JD Assistant Professor, Dept. of International Health Johns Hopkins Bloomberg School of Public Health Core Faculty & Associate Director for Global Programs Johns Hopkins Berman Institute of Bioethics Tanya Matthe
Long COVID can live up to its name. A new study shows that certain symptoms of the condition, such as brain fogginess, can still be experienced in people with long COVID two years after the original infection.
Long COVID can live up to its name. A new study shows that certain symptoms of the condition, such as brain fogginess, can still be experienced in people with long COVID two years after the original infection.
Treatment with Wegovy led to a 20% reduction in the relative risk of cardiovascular complications or death, a finding that could further shift how doctors treat obesity.
Data Sharing and Pragmatic Clinical Trials: Law & Ethics Amidst a Changing Policy Landscape Description Kayte Spector-Bagdady and Stephanie Morain discuss the impact of a changing policy landscape on data sharing and pragmatic clinical trials. Biography Stephanie Morain, PhD, MPH Assistant Professor, Bloomberg School of Public Health, Johns Hopkins University Ethics and Regulatory Core Co-chair Kayte Spector-Bagdady, JD, MBioethics Associate Director, Center for Bioethics & Social Scien
Fitness trackers help you stay healthy by keeping count of your steps and monitoring your heart rate, driving you on to hit those cardio goals. New research from ETH Zürich in Switzerland could see future wearable devices (with perhaps a few implants and a touch of genetic engineering) boost our health directly.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
The Indianapolis drugmaker is now worth more than $500 billion, higher than any other pharmaceutical company, as analysts project lucrative markets for its obesity and Alzheimer's drugs.
The Stepped Wedge Cluster Randomized Trial: Friend or Foe? Description Dr. Monica Taljaard and Dr. David Magnus discuss the pros and cons of the stepped wedge cluster randomized trial. Biography Monica Taljaard, PhD Senior Scientist, Clinical Epidemiology Program, Ottawa Hospital Research Institute Full Professor, Epidemiology and Community Medicine, University of Ottawa David Magnus, PhD Professor of Medicine and Biomedical Ethics and Professor of Pediatrics, Medicine, and by courtesy of Bioeng
Of all the senses we love to indulge, scent is often neglected – but the right smells could be just what your brain needs to keep it whirring in old age.
The planned facility in the biotech hotspot of Cambridge will include incubator space for startups and adds to Astellas’ R&D footprint in the Boston area.
Ethical Considerations When Vulnerable Populations are Subjects in Pragmatic Trials Description Dr. Emily Largent discusses ethical considerations when vulnerable populations are subjects in pragmatic trials. Biography Emily A. Largent, JD, PhD, RN Emanuel & Robert Hart Assistant Professor of Medical Ethics and Health Policy Department of Medical Ethics and Health Policy University of Pennsylvania Perelman School of Medicine The post Ethical Considerations When Vulnerable Populations are Sub
The pharmaceutical industry in the country is waiting for the positive government response on the suggestions on the draft notification about the list of over-the-counter (OTC) drugs under Schedule K of Drug Rules 1945 and laid down specific provisions for its regulation in the country.
Informing and Consenting: What are the Goals? Description Drs. Pearl O’Rourke, David S. Wendler, Miguel Vazquez, and Michael Ho discuss the goals of informing and consenting. Biography Pearl O’Rourke, MD (retired) Harvard Medical School Ethics and Regulatory Core Co-chair David S. Wendler, PhD, MA Senior Researcher, Department of Bioethics, NIH Clinical Center Miguel Vasquez, MD Professor of Internal Medicine, UT Southwestern Medical Center ICD-Pieces Demonstration Project PI Michael Ho, MD, PhD
Ten collective stakeholders of Indian healthcare industry, including the industry associations of medical devices manufacturers, patient interest group, and healthcare providers, have jointly demanded to the Union health minister Dr Mansukh Mandaviya to recall the New Drugs, Medical Devices & Cosmetics Bill, 2023 that is listed to be tabled in Parliament during the ongoing session.
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
The job cuts will affect “all areas of the company” and, combined with other cost-reduction efforts, lead to annualized savings of over $100 million, Emergent said.
Joe Ali, a longtime member of the NIH Pragmatic Trials Collaboratory’s Ethics and Regulatory Core, will present “Advancing Justice and Equity in Pragmatic Clinical Trials.” The presentation is part of the Spotlight on Pain Management series of the VA HSR&D Cyberseminars. Advance registration is required. VA HSR&D Cyberseminars: Spotlight on Pain Management “Advancing Justice and Equity in Pragmatic Clinical Trials” Joe Ali, PhD Johns Hopkins University Advan
To help the pharmaceutical companies located in Baddi and in Solan district of Himachal Pradesh (HP) to better their performances further, the Baddi Barotiwala Nalagarh Development Authority (BBNDA), under the Government of HP, will organize a National Pharma Summit in September in which all stakeholders of the Indian pharmaceutical sector and government officials of the […]
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
From left: Dr. Steven George, Dr. Vincent Mor, and Dr. Angelo Volandes In an interview at this year’s NIH Pragmatic Trials Collaboratory Steering Committee annual meeting, Drs. Steven George, Vincent Mor, and Angelo Volandes discussed the complexity of intervention delivery in pragmatic clinical trials and the impact it can have on researchers’ ability to discern trial results. “Without delving deeply into the way in which an intervention can be integrated into an operating sys
Despite having a considerable burden of lung cancer, India does not have a formal screening programme for lung cancer, experts have raised alarm. Therefore, it is high time to implement the same as early detection of lung cancer is crucial.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content